血清生物标志物可识别需行MRI的重症创伤性脑损伤患者
本研究基于CENTER-TBI研究数据,纳入65例符合标准的TBI患者(30例中重度、35例院前GCS未记录),评估伤后24小时内血清GFAP、NFL、NSE、S100B、Tau、UCH-L1与MRI Adams-Gentry分级轴索损伤的关联。结果显示54例(83%)存在轴索损伤、33例(51%)累及脑干;中重度TBI患者中脑干损伤与NSE、Tau、UCH-L1、GFAP浓度升高相关。若不愿遗漏任何脑干损伤,NSE可避免最多20%的MRI转运;若接受94%敏感度,GFAP可避免30%转运,且无额外净费用(英国节省达99英镑、美国达612美元)。插管且院前GCS未记录的患者中未发现蛋白与轴索损伤的关联。
要点
- 中重度TBI重症患者中,若不愿遗漏任何脑干损伤(Adams-Gentry 3级),NSE可避免最多20%的MRI转运。
- 若接受94%敏感度以权衡转运相关并发症,GFAP可避免30%的MRI转运。
- 采用生物标志物策略无额外净费用,英国节省达99英镑、美国达612美元。
- 插管且院前GCS未记录的患者中,未发现血清蛋白与轴索损伤的关联。
- 65例患者中MRI检出轴索损伤54例(83%)、脑干受累33例(51%)。
适用人群与场景
- 来自CENTER-TBI研究的TBI患者,年龄≥16岁,GCS<13或插管且院前GCS未记录,CT Marshall评分<3,伤后≤24小时采样血清生物标志物,伤后<30天行MRI。
诊断标准与关键阈值
- MRI轴索损伤程度采用Adams-Gentry分级,脑干损伤为Adams-Gentry 3级。
- 生物标志物阈值基于不同最低敏感度设定:不愿遗漏任何脑干损伤时采用NSE;接受94%敏感度时采用GFAP。
研究设计与关键结果
- 研究类型为基于CENTER-TBI研究数据的分析,纳入65例患者(30例中重度TBI、35例院前GCS未记录),轴索损伤54例(83%)、脑干受累33例(51%)。
- 中重度TBI患者中,脑干损伤与较高浓度的NSE、Tau、UCH-L1和GFAP相关。
- 若临床医生不愿遗漏任何脑干损伤,NSE可避免最多20%的MRI转运。
- 若接受94%敏感度以考虑潜在转运相关并发症,GFAP可避免30%的转运。
- 无额外净费用,英国节省达99英镑、美国节省达612美元。
- 插管且院前GCS未记录的患者中,未发现蛋白与轴索损伤的关联。
证据类型、等级与局限
- 证据类型:基于CENTER-TBI研究的分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,血清蛋白生物标志物显示出在中重度TBI重症患者中安全减少MRI转运数量的潜力,且无额外费用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Magnetic resonance imaging (MRI) carries prognostic importance after traumatic brain injury (TBI), especially when computed tomography (CT) fails to fully explain the level of unconsciousness. However, in critically ill patients, the risk of deterioration during transfer needs to be balanced against the benefit of detecting prognostically relevant information on MRI. We therefore aimed to assess if day of injury serum protein biomarkers could identify critically ill TBI patients in whom the risks of transfer are compensated by the likelihood of detecting management-altering neuroimaging findings.
METHODS: Data were obtained from the Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) study. Eligibility criteria included: TBI patients aged ≥ 16 years, Glasgow Coma Score (GCS) < 13 or patient intubated with unrecorded pre-intubation GCS, CT with Marshall score < 3, serum biomarkers (GFAP, NFL, NSE, S100B, Tau, UCH-L1) sampled ≤ 24 h of injury, MRI < 30 days of injury. The degree of axonal injury on MRI was graded using the Adams-Gentry classification. The association between serum concentrations of biomarkers and Adams-Gentry stage was assessed and the optimum threshold concentration identified, assuming different minimum sensitivities for the detection of brainstem injury (Adams-Gentry stage 3). A cost-benefit analysis for the USA and UK health care settings was also performed.
RESULTS: Among 65 included patients (30 moderate-severe, 35 unrecorded) axonal injury was detected in 54 (83%) and brainstem involvement in 33 (51%). In patients with moderate-severe TBI, brainstem injury was associated with higher concentrations of NSE, Tau, UCH-L1 and GFAP. If the clinician did not want to miss any brainstem injury, NSE could have avoided MRI transfers in up to 20% of patients. If a 94% sensitivity was accepted considering potential transfer-related complications, GFAP could have avoided 30% of transfers. There was no added net cost, with savings up to £99 (UK) or $612 (US). No associations between proteins and axonal injury were found in intubated patients without a recorded pre-intubation GCS.
CONCLUSIONS: Serum protein biomarkers show potential to safely reduce the number of transfers to MRI in critically ill patients with moderate-severe TBI at no added cost.
参考来源
- Richter S, Winzeck S, Czeiter E, et al. Serum biomarkers identify critically ill traumatic brain injury patients for MRI. Crit Care. 2022. PMID: 36447266. doi:10.1186/s13054-022-04250-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。